Pirfenidone improves survival in IPF: results from a real-life study

BACKGROUND: Pirfenidone is an antifibrotic compound approved for the treatment of idiopathic pulmonary fibrosis (IPF). We present our real-world experience in terms of Pirfenidone’s effect on mortality and adverse events profile outside the restrictions of a clinical trial. METHODS: This is a retros...

Descripción completa

Detalles Bibliográficos
Autores principales: Margaritopoulos, George A., Trachalaki, Athina, Wells, Athol U., Vasarmidi, Eirini, Bibaki, Eleni, Papastratigakis, George, Detorakis, Stathis, Tzanakis, Nikos, Antoniou, Katerina M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251092/
https://www.ncbi.nlm.nih.gov/pubmed/30470213
http://dx.doi.org/10.1186/s12890-018-0736-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251092/
https://www.ncbi.nlm.nih.gov/pubmed/30470213
http://dx.doi.org/10.1186/s12890-018-0736-z

Ejemplares similares